Prognosis for Scleroderma

The prognosis of scleroderma varies for patients who have systemic sclerosis. It is often complicated to make a prognosis in the early stages of the disease. The prognosis for scleroderma for patients with limited sclerosis who do not build up pulmonary hypertension is good.

Men who develop the disease, patients with diffuse scleroderma, and patients who experience kidney, lung, and heart involvement normally have a worse prognosis. The first thing to identify with is that the Treatment for Scleroderma is a slow development. It likely took some years for a person to become difficult in scleroderma and it likely will take several months to see significant results.

There is no cure for systemic sclerosis and the objective of treatment is to reduce symptoms and maintain function. Most treatments are used for a particular symptom or the particular organ involved. It is essential for patients with scleroderma to be involved in treatment decisions. Patients with systemic sclerosis should not smoke.

Primary Scleroderma Skin Treatment involvement is to apply moisturizers for example topical steroids and emollients. Psoralen and ultraviolet A therapy may also be use. This treatment involves exposing the patient to increasing amounts of ultraviolet A rays with an oral or topical substance called psoralen, which makes the skin more sensitive to treatment and improves its usefulness.